ABRAXAS2 and cancer: Nearly half of all cancers are p53‐mutated (Liu et al., 2013; Stokłosa and Gołąb, 2005; Szymañska and Hainaut, 2003), suggesting that the p53‐independent tumor‐suppressive effect of FAM175B in ESCC also exists in other cancer types with p53 mutations.